ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.38
−4.08%Next report
Analyst consensus
- Next report date
- Oct 27, 2026
- EPS estimate
- $0.17
- Revenue estimate
- $141.7M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- $0.11
- EPS estimate
- $0.06
- Revenue actual
- $129.9M
- Revenue estimate
- $118.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +27.7%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $39
- PT range
- $38 – $40
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | $0.06 | $0.11 | Beat 99.71% | $129.9M |
| May 6, 2026 | -$0.02 | -$0.09 | Miss -350.00% | $105.4M |
| Feb 25, 2026 | $0.03 | $0.13 | Beat 333.33% | $129.5M |
| Aug 6, 2025 | -$0.18 | -$0.13 | Beat 27.78% | $81.5M |
| Aug 14, 2024 | -$0.48 | -$0.42 | Beat 12.50% | $30.9M |
| Feb 27, 2024 | -$0.65 | -$0.72 | Miss -10.77% | $13.5M |
| Nov 3, 2023 | -$0.90 | -$0.73 | Beat 18.89% | $38.1M |
| Feb 28, 2023 | -$1.37 | -$1.18 | Beat 13.87% | $3.0M |
| Aug 4, 2022 | -$1.38 | -$1.31 | Beat 5.07% | — |
| May 5, 2022 | -$1.42 | -$1.27 | Beat 10.56% | — |
| Feb 22, 2022 | -$1.41 | -$1.42 | Miss -0.71% | — |
| Nov 4, 2021 | -$1.09 | -$1.14 | Miss -4.59% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 27, 2026